In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 8, 1996, Pages 1910-1913

  Perfect, John R ^a   Cox, Gary M ^a   Dodge, Richard K ^a   Schell, Wiley A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CORTISONE ACETATE; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; TRIAZOLE DERIVATIVE;

ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG SENSITIVITY; FUNGAL MENINGITIS; INTRAMUSCULAR DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; TABLET;

EID: 0029817614     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.8.1910     Document Type: Article

References (19)

1. Bennett, J. E., W. Dismukes, R. J. Duma, G. Medoff, M. A. Sande, H. Gallis, J. Leonard, B. T. Fields, M. Bradshaw, H. Haywood, Z. A. McGee, T. R. Cate, C. G. Cobbs, J. F. Warner, and D. W. Alling. 1979. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N. Engl. J. Med. 301:126-131.
2. Bozzette, S. A., R. A. Larsen, and J. Chin. 1991. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N. Engl. J. Med. 324: 580-584.
3. Denning, D. W., R. M. Tucker, L. H. Hanson, J. R. Hamilton, and D. A. Stevens. 1989. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch. Intern. Med. 149:2301-2308.
4. Dismukes, W. E., G. Cloud, H. A. Gallis, T. M. Kerkering, G. Medoff, P. L. Craven, L. G. Kaplowitz, J. F. Fisher, C. R. Gregg, C. A. Bowles, S. Shadomy, A. M. Stamm, R. B. Diasio, L. Kaufman, S.-J. Soong, W. Blackwelder, and National Institute of Allergy and Infectious Diseases Mycoses Study Group. 1987. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N. Engl. J. Med. 317:334-341.
5. Nassar, F., E. Brummer, and D. A. Stevens. 1995. Different components in human serum inhibit multiplication of Cryptococcus neoformans and enhance fluconazole activity. Antimicrob. Agents Chemother. 39:2490-2493.
6. National Committee for Clinical Laboratory Standards. 1992. Reference method for broth dilution antifungal susceptibility testing of yeast; proposed standard M27-P. National Committee for Clinical Laboratory Standards, Villanova, Pa.
7. Paugam, A., J. Dupuy-Camet, P. Blanche, J. P. Gangneux, C. Tourte-Schaefer, and D. Sicard. 1994. Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin. Infect. Dis. 19:975.
8. Perfect, J. R., and D. T. Durack. 1982. Treatment of experimental cryptococcal meningitis with amphotericin B, 5-fluorocytosine and ketoconazole. J. Infect. Dis. 146:429-435.
9. Perfect, J. R., and D. T. Durack. 1985. Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis. Antimicrob. Agents Chemother. 28:751-755.
10. Perfect, J. R., S. D. R. Lang, and D. T. Durack. 1980. Chronic cryptococcal meningitis: a new experimental model in rabbits. Am. J. Pathol. 101:177-194.
11. Perfect, J. R., D. V. Savani, and D. T. Durack. 1986. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob. Agents Chemother. 29:579-583.
12. Perfect, J. R., D. V. Savani, and D. T. Durack. 1993. Uptake of itraconazole by alveolar macrophages. Antimicrob. Agents Chemother. 37:903-904.
13. Perfect, J. R., and K. A. Wright. 1994. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidiasis. J. Antimicrob. Chemother. 33:73-81.
14. Perfect, J. R., K. A. Wright, M. M. Hobbs, and D. T. Durack. 1989. Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH 39304. Antimicrob. Agents Chemother. 33:1735-1740.
15. Powderly, W. G., D. M. Finkelstein, J. Feinberg, P. Frame, W. He, C. van der Horst, S. L. Koletar, M. E. Eyster, J. Carey, H. Waskin, T. M. Hooton, N. Hyslop, S. A. Spector, and S. A. Bozzette. 1995. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 332:700-705.
16. Saag, M. S., W. G. Powderly, G. A. Cloud, P. Robinson, M. H. Grieco, P. K. Sharkey, S. E. Thompson, A. Sugar, C. U. Tuazon, J. F. Fisher, N. Hyslop, J. M. Jacobson, R. Hafner, and W. F. Dismukes. 1992. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N. Engl. J. Med. 326:83-89.
17. Velez, J. D., R. Allendoerfer, M. Luther, M. G. Rinaldi, and J. R. Graybill. 1993. Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J. Infect. Dis. 168:508-510.
18. Viviani, M. A., A. M. Tortorano, M. Langer, M. Alma-Viva, E. Negri, S. Christina, S. Soccia, R. De Maria, R. Fiocchi, and P. Ferrazzi. 1989. Experience with itraconazole in cryptococcosis and aspergillosis. J. Infect. 18:151-165.
19. Wright, K. A., J. R. Perfect, and W. Ritter. 1990. The pharmacokinetics of BAY R3783 and its efficacy in the treatment of experimental cryptococcal meningitis. J. Antimicrob. Chemother. 26:387-397.